Devoted to the life sciences with persistence, Kexing Biopharm has focused on the innovation and industrialization of biopharmaceuticals,and established a relatively complete system of pharmaceutical R&D, covering pharmaceutical innovation capabilities from pharmaceutical discovery, pharmaceutical research, preclinical research and clinical research to industrialized production.

we have established a complete system of pharmaceutical R&D innovation, covering pharmaceutical innovation capabilities from pharmaceutical discovery, pharmaceutical research, preclinical research and clinical research to industrialized production. Depending on prokaryotic cell technology, eukaryotic cell technology and viable bacteria technology, we have built 7 world-leading technology platforms, including recombinant protein secretion and expression platform, recombinant protein therapeutics industrialization platform, long-act-ing recombinant protein platform, microeco-logical agent R&D and industrialization platform, strain platform, Antibody Technology Platform, and Vector Vaccine Technology Platform.

At present, we have obtained 42 patents, more than 10 biopharmaceutical projects are being studied. An R&D team composed of over 200 members from the fields of molecular biology, pharmacy, pharmaceutics, etc., with core technicians engaged in R&D for more than 20 years.